{"id":35427,"date":"2026-07-14T11:00:00","date_gmt":"2026-07-14T09:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=09ec812d2ddddab173427f231732acc7"},"modified":"2026-07-14T11:00:00","modified_gmt":"2026-07-14T09:00:00","slug":"agendia-announces-definitive-mandatory-swiss-health-insurance-reimbursement-for-mammaprint","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=35427","title":{"rendered":"Agendia Announces Definitive Mandatory Swiss Health Insurance Reimbursement for MammaPrint"},"content":{"rendered":"

\nEffective 1 July 2026, Switzerland\u2019s FOPH completes its review of multigene expression testing, formally deciding to continue reimbursement indefinitely<\/i><\/p><\/a><\/a>

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia\u00ae, Inc., a leader in precision oncology for breast cancer, today announced the official ruling by the Swiss Federal Office of Public Health (FOPH) to grant definitive, mandatory health insurance (Obligatorische Krankenpflegeversicherung, or OKP) coverage for multigene expression tests, including MammaPrint\u00ae for eligible patients with early-stage breast cancer.<\/p>

\nThe tests are intended to help guide chemotherapy decision-making and have been covered by insurance since 1 January 2015, subject to evaluation. Effective 1 July 2026, this regulatory update successfully concludes a provisional evaluation framework establishing the diagnostics as a mandatory insurance obligation in the Swiss healthcare system.<\/p>

\nActing on a formal recommendation from the Federal Commission for General Benefits and Policy Issues (ELGK), the FOPH has amended Annex 1 of the Healthcare Benefits Ordinance (KLV) based on a comprehensive Health Technology Assessment (HTA).<\/p>

\nThe HTA report focused on the clinical efficacy, cost effectiveness, cost implications for statutory health insurance providers, and the ethical, legal, social, and organizational aspects of the four multigene expression tests currently used in Switzerland. The report confirmed MammaPrint\u2019s ability to predict risk of recurrence, and together with relevant evaluations from other countries, informed the FOPH\u2019s final assessment of the healthcare benefits criteria.<\/p>

\nEligibility for mandatory OKP reimbursement requires the patient\u2019s breast cancer tumor fulfill the following conditions:<\/p>